Interleukin-1 beta (IL-1β) is a key pro-inflammatory cytokine that serves as both a molecular mediator of neuroinflammation and a valuable biomarker for neurodegenerative disease progression. This page provides comprehensive coverage of IL-1β's biology, its role in neurodegeneration, and its clinical applications as a biomarker. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Inflammatory Cytokine | [4]
| Target | IL-1β | [5]
| Sample Type | CSF, Blood, Serum | [6]
| Diseases | AD, PD, ALS, HD, Stroke, TBI, FTD | [7]
| Role | Pro-inflammatory cytokine, innate immunity | [8]
| Detection Methods | ELISA, Simoa, MSD, Luminex | [9]
Interleukin-1 beta (IL-1β) is a member of the interleukin-1 family of cytokines, produced primarily by activated microglia, astrocytes, peripheral macrophages, and to a lesser extent by neurons and endothelial cells. It is synthesized as a 31 kDa inactive pro-form (pro-IL-1β) that requires cleavage by caspase-1 within the NLRP3 inflammasome complex to generate the 17 kDa biologically active form 1. This cytokine plays a central role in neuroinflammation and has been implicated in the pathogenesis of virtually all neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD) 2. [10]
IL-1β is encoded by the IL1B gene located on chromosome 2q14.1 in humans. The protein consists of 269 amino acids in its pro-form and 153 amino acids in its mature form after caspase-1 cleavage 1. The three-dimensional structure reveals a β-barrel fold similar to fibroblast growth factors, despite minimal sequence homology.
The processing of IL-1β involves two distinct signals 4:
IL-1β signals through the IL-1 receptor type I (IL-1R1), which recruits the IL-1 receptor accessory protein (IL-1RAcP) to form a high-affinity signaling complex 5. This triggers activation of multiple downstream pathways:
| Pathway | Key Components | Cellular Effects |
|---|---|---|
| NF-κB | IKK complex, p65/p50 | Pro-inflammatory gene transcription |
| MAPK | p38, JNK, ERK1/2 | Stress response, apoptosis |
| MyD88 | MyD88 adaptor | TLR/IL-1R signaling |
| IRAK | IRAK1/4 kinases | Inflammation amplification |
IL-1β serves as a significant biomarker in AD pathophysiology 2:
A meta-analysis of 2,847 AD patients and 2,169 controls demonstrated significantly elevated CSF IL-1β levels (standardized mean difference: 0.42, p < 0.001) 9. Longitudinal studies show that elevated IL-1β at baseline predicts conversion from mild cognitive impairment (MCI) to AD with an odds ratio of 2.3 10.
In PD, IL-1β contributes to dopaminergic neuron degeneration 2:
IL-1β is a marker of disease activity in ALS 2:
In HD, IL-1β contributes to striatal neurodegeneration 2:
IL-1β serves as a biomarker in FTD subtypes 2:
| Method | Sensitivity | Throughput | Clinical Use |
|---|---|---|---|
| ELISA | 1-5 pg/mL | Low | Research, clinical trials |
| Simoa | 0.2-0.5 fg/mL | Medium | Ultra-sensitive detection |
| Meso Scale Discovery | 0.1-1 pg/mL | High | Multiplex panels |
| Luminex | 1-10 pg/mL | High | Cytokine panels |
| Electrochemiluminescence | 0.5-2 pg/mL | High | Clinical diagnostics |
Targeting IL-1β has emerged as a therapeutic strategy in neurodegeneration 2:
| Drug | Mechanism | Stage | Indication |
|---|---|---|---|
| Anakinra | IL-1R antagonist | Phase 2 | AD, ALS |
| Canakinumab | Anti-IL-1β mAb | Phase 2/3 | AD, CAD |
| Lodrgenumab | Anti-IL-1β mAb | Phase 1 | AD |
| Diacerein | IL-1 inhibitor | Phase 2 | PD |
| Disease | CSF Level | Blood Level | Correlation | Prognostic Value |
|---|---|---|---|---|
| AD | ↑ Elevated | ↑ Variable | Disease severity | Moderate |
| PD | ↑ Elevated | ↑ Elevated | Motor scores | Moderate |
| ALS | ↑ Elevated | ↑ Elevated | Progression rate | High |
| HD | ↑ Elevated | ↑ Variable | Disease stage | Moderate |
| FTD | ↑ Elevated | ↑ Variable | Behavioral scores | Low-Moderate |
IL-1β often correlates with other neurodegenerative disease biomarkers:
With tau markers: Elevated IL-1β correlates with CSF t-tau and p-tau levels 9
With neurofilament: Co-elevation with NfL indicates combined neuronal injury and inflammation
With GFAP: Astrocyte activation markers elevated together
With sTREM2: Microglial activation shows coordinated changes
Interleukin-6 (IL-6) in Neurodegeneration
TNF-alpha - Biomarker
sTREM2 (Soluble TREM2) - Biomarker---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)---biomarker)
Neuroinflammation Pathway
Microglia Entity
NLRP3 Inflammasome
TREM2 Signaling Pathway
NLRP3 inflammasome activation in neuroinflammation (2012). 2012. ↩︎
Neuroinflammation in neurodegenerative disorders (2017). 2017. ↩︎
Two-step model for NLRP3 inflammasome activation (2019). 2019. ↩︎
IL-1β increases BACE1 expression and Aβ production (2013). 2013. ↩︎
IL-1β promotes tau phosphorylation via GSK-3β (2013). 2013. ↩︎